16
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Inflammation in Diabetic Kidney Disease

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Diabetes is a growing public health problem. Diabetic kidney disease (DKD) is the most prevalent chronic renal disease and the major cause of end-stage renal failure worldwide, predominantly due to the increase of Type 2 diabetes associated with obesity. The intimate mechanisms leading to the development and progression of renal injury in DKD are not well understood, but current knowledge indicates that its pathogenesis is multifactorial, where the immune response and inflammation appear to be relevant factors. Summary: This review summarizes the role of relevant inflammatory molecules and pathways that participate in the development of DKD. Likewise, we focused on the new therapeutic approaches based on anti-inflammatory effects of different drugs. Key Messages: This new pathogenic perspective of DKD as an inflammatory condition leads to novel horizons, such as the potential role of inflammatory signaling pathways and their downstream products as emerging biomarkers and promising therapeutic targets.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          2019
          September 2019
          01 October 2018
          : 143
          : 1
          : 12-16
          Affiliations
          [_a] aServicio de Nefrología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
          [_b] bServicio de Nefrología, Hospital Torrecárdenas, Almería, Spain
          [_c] cGrupo de Investigación Traslacional Vascular y Renal, Instituto de Investigación Biomédica IRBLLEIDA, Lleida, Spain
          [_d] dRed de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain
          [_e] eInstituto de Investigación Sanitaria-Fundación Jiménez Díaz-Universidad Autónoma de Madrid y Fundación Renal Iñigo Álvarez de Toledo-Instituto Reina Sofía de Investigación Nefrológica, Madrid, Spain
          [_f] fGEENDIAB (Grupo Español para el Estudio de la Nefropatía Diabética), Sociedad Española de Nefrología, Spain
          [_g] gUnidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
          Author notes
          *Dr. Juan F. Navarro-González, Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Carretera del Rosario 145, ES–38010 Santa Cruz de Tenerife (Spain), E-Mail jnavgon@gobiernodecanarias.org
          Article
          493278 Nephron 2019;143:12–16
          10.1159/000493278
          30273931
          986e13ba-f0ab-46b8-8cbc-fa8968dfab62
          © 2018 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 29 June 2018
          : 10 August 2018
          Page count
          Tables: 1, Pages: 5
          Categories
          Clinical Practice: Mini-Review

          Cardiovascular Medicine,Nephrology
          Inflammation,Therapies targeting inflammation,Diabetes,Diabetic kidney disease

          Comments

          Comment on this article